Lung Cancer Clinical Trials in Atlanta

Showing 641-649 of 649 trials

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

NCT00051974

The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.

Non-Small Cell Lung Cancer

Millennium Pharmaceuticals, Inc.155 participantsStarted Dec 2002

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +17 more locations

COMPLETEDPhase 212 miles

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

NCT00116610

This is a Phase II research study that is designed for patients who have small cell lung cancer (SCLC) that is no longer responding to treatment. Patients will receive picoplatin, a new platinum-based agent that is currently under investigation, in 21-day cycles.

Small Cell Lung Cancer

Poniard Pharmaceuticals75 participantsStarted Jun 2005

Hot Springs, Arkansas, United States • Los Angeles, California, United States • Palm Springs, California, United States +52 more locations

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Lung Cancer Trials in Other Cities

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide

Other Conditions in Atlanta